An assessment of statin safety by nephrologists

被引：42

作者：

Kasiske, BL

Wanner, C

O'Neill, WC

机构：

[1] Hennepin Cty Med Ctr, Dept Med, Minneapolis, MN 55415 USA

[2] Univ Wurzburg, Wurzburg, Germany

[3] Emory Univ, Atlanta, GA 30322 USA

来源：

AMERICAN JOURNAL OF CARDIOLOGY | 2006年 / 97卷 / 8A期

关键词：

D O I：

10.1016/j.amjcard.2005.12.015

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Recently, concerns regarding potential adverse effects of the statins on the kidney have been raised. The Kidney Expert Panel of the National Lipid Association's (NLA) Safety Task Force, made up of 3 nephrologists, was convened to review all of the currently available evidence pertinent to determining whether statins cause kidney injury, independent of the known, rare mechanisms of rhabdomyolysis and allergic, drug-induced, interstitial nephritis. The Panel reviewed published and unpublished evidence and found none that suggested that statins, when used in doses currently approved by the US Food and Drug Administration (FDA), cause kidney injury. (c) 2006 Elsevier Inc. All rights reserved.

引用

收藏

页码：82C / 85C

页数：4

相关论文

共 18 条

[1] The effect of statins versus untreated dyslipidaemia on renal function in patients with coronary heart disease. A subgroup analysis of the Greek atorvastatin and coronary heart disease evaluation (GREACE) study [J].

Athyros, VG ;

Mikhailidis, DP ;

Papageorgiou, AA ;

Symeonidis, AN ;

Pehlivanidis, AN ;

Bouloukos, VI ;

Elisaf, M .

JOURNAL OF CLINICAL PATHOLOGY, 2004, 57 (07) :728-734

[2] Study of Heart and Renal Protection (SHARP) [J].

Baigent, C ;

Landry, M .

KIDNEY INTERNATIONAL, 2003, 63 :S207-S210

[3] A controlled, prospective study of the effects of atorvastatin on proteinuria and progression of kidney disease [J].

Bianchi, S ;

Bigazzi, R ;

Caiazza, A ;

Campese, VM .

AMERICAN JOURNAL OF KIDNEY DISEASES, 2003, 41 (03) :565-570

[4] Meta-analysis of large randomized controlled trials to evaluate the impact of statins on cardiovascular outcomes [J].

Cheung, BMY ;

Lauder, IJ ;

Lau, CP ;

Kumana, CR .

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2004, 57 (05) :640-651

[5] Excerpts from the United States Renal Data System 2002 Annual Data Report: Atlas of End-Stage Renal Disease in the United States - Preface [J].

Collins, AJ ;

Kasiske, B ;

Herzog, C ;

Chen, SC ;

Everson, S ;

Constantini, E ;

Grimm, R ;

McBean, M ;

Xue, J ;

Chavers, B ;

Matas, A ;

Manning, W ;

Louis, T ;

Ma, J ;

Pan, W ;

Liu, JN ;

Li, SY ;

Roberts, T ;

Dalleska, F ;

Snyder, J ;

Ebben, J ;

Frazier, E ;

Sheets, D ;

Johnson, R ;

Li, SL ;

Dunning, S ;

Berrini, D ;

Guo, HF ;

Palzer, M ;

Solid, C ;

Arko, C ;

Daniels, F ;

Wang, XY ;

Gilbertson, D ;

St Peter, W ;

Frederick, P ;

Eggers, P ;

Agodoa, L .

AMERICAN JOURNAL OF KIDNEY DISEASES, 2003, 41 (04) :V-IX

[6] PROTEINURIA AS COMPLICATION OF SIMVASTATIN TREATMENT [J].

DESLYPERE, JP ;

DELANGHE, J ;

VERMEULEN, A .

LANCET, 1990, 336 (8728) :1453-1453

[7] Why do we need a statin trial in hemodialysis patients? [J].

Fellström, BC ;

Holdaas, H ;

Jardine, AG .

KIDNEY INTERNATIONAL, 2003, 63 :S204-S206

[8] Effect of lipid reduction on the progression of renal disease: A meta-analysis [J].

Fried, LF ;

Orchard, TJ ;

Kasiske, BL .

KIDNEY INTERNATIONAL, 2001, 59 (01) :260-269

[9] Effect of fluvastatin on cardiac outcomes in renal transplant recipients:: a multicentre, randomised, placebo-controlled trial [J].

Holdaas, H ;

Fellström, B ;

Jardine, AG ;

Holme, I ;

Nyberg, G ;

Fauchald, P ;

Grönhagen-Riska, C ;

Madsen, S ;

Neumayer, HH ;

Cole, E ;

Maes, B ;

Ambühl, P ;

Olsson, AG ;

Hartmann, A ;

Solbu, DO ;

Pedersen, TR .

LANCET, 2003, 361 (9374) :2024-2031

[10] Statin safety: Lessons from new drug applications for marketed statins [J].

Jacobson, TA .

AMERICAN JOURNAL OF CARDIOLOGY, 2006, 97 (8A) :44C-51C